Abstract
Anti-TNF therapy is the most important treatment for inflammatory bowel disease patients. However, primary nonresponders are frequent and clinical recurrence under maintenance therapy is reported in 40% of the treated patients. The aim of this article is to explain the most important targets for the future of treatments in inflammatory bowel disease and to report the results of these news drugs in clinical practice. Two Phase III studies clearly indicate the interest of golimumab and vedolizumab in induction and maintenance treatment for ulcerative colitis patients. Soon it will be possible to analyze the principal regulation defect in each patient to design a more personalized treatment. Before this step, it is important first to try to optimize treatment and then to consider a switch to another drug.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
